bioAffinity presents CyPath Lung data at NAVREF 2026; cites 92% sensitivity in veteran study

bioAffinity Technologies, Inc.

Two posters presented Sept 27-30, 2026 in Arlington, VA: one on 3 clinical cases, one on FlowPath Lung study.
FlowPath Lung: 2,000-patient longitudinal study in veterans/military, enrolling at 12 VA centers and 2 military hospitals.
CyPath Lung reported 92% sensitivity, 87% specificity, 99% NPV for pulmonary nodules ≤20 mm.
Poster cites 2024 economic analysis projecting hundreds of millions in potential VA screening savings.
Company appears with new distribution partner AvMEDICAL at first joint federal healthcare market engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.